Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. SPG

Go back to Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
ENANTA PHARM (NASDAQ: ENTA) Delayed: 14.08 +0.06 (0.43%)
Previous Close $14.02    52 Week High $34.49 
Open $13.92    52 Week Low $20.39 
Day High $14.23    P/E N/A 
Day Low $13.45    EPS $-3.18 
Volume 233,451